AbbVie Inc.（ABBV）の適正株価とPER分析

Drug Manufacturers - General · NYSE

AbbVie Inc. の適正株価はいくらですか？

2026-08-21 時点で、AbbVie Inc.（ABBV）の1株あたり利益 $3.57 に 50.0x の利益マルチプルを適用すると、1株あたりの適正株価の試算は約 $175.28 となります。現在株価は $265.01 です。

利益マルチプルによる適正株価は、選ぶマルチプル次第で大きく変わります。感応度グリッド全体では、試算は $151.5 から $201.98 の範囲に広がります。これは利益に紐づく相対的な試算であり、確定的な事実ではありません。キャッシュフローに基づく視点については、DCFページの本質的価値の試算をご覧ください。

PERモデルの仕組み · PERモードで再計算 · ABBV の本質的価値（DCFの視点）

AbbVie Inc.（ABBV）は割高ですか？

$265.01 の水準で、ABBV はPERベースの適正株価の試算を上回って取引されており、市場が適用利益マルチプルを超えるプレミアムを支払っていることを意味します。このモデルでは、利益が株価に追いつかない限り、株価は割高に見えます。

評価：Charlie Wang（元監査人）

会社概要

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

財務指標 — ABBV PERバリュエーションデータ

よくある質問

関連リンク

• ABBV のDCFバリュエーションを見る → — 割引キャッシュフロー分析による本質的価値
• PER法の解説 — PERバリュエーションのステップ別ガイド
• DCF法の解説 — 割引キャッシュフロー分析のガイド
• PER（株価収益率） — 株価収益率の理解
• 本質的価値 — 株式の適正株価を評価する方法